Autoimmune hepatitis research hub

A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)

This study is looking into a new treatment, VAY736, for adults with a liver condition called autoimmune hepatitis. It aims to see if VAY736 is safe and helps improve liver blood tests for people whose current treatments aren't working well or cause side effects.